Compound Profiles
MK-677
Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue
Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..
Tesamorelin
GHRH Analog | Visceral Fat Reduction
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take MK-677 with Tesamorelin?
Yes, but with caution. Both MK-677 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is MK-677 and Tesamorelin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.
What are the interactions between MK-677 and Tesamorelin?
Both MK-677 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time MK-677 and Tesamorelin?
MK-677 has a half-life of ~24 hours and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.